An update on emerging drugs for asthma

Bibliography

• Anandan C, Nurmatov U, van Schayck OC, Sheikh A. Is the prevalence of asthma declining? Systematic review of epidemiological studies. Allergy 2010;65(2):152-67
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Pathophysiology of allergic inflammation. Immunol Rev 2011;242(1):31-50
   PubMedGoogle Scholar
• Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 2005;25:552-63
   PubMed Web of Science ®Google Scholar
• Berger WE. New approaches to managing asthma: a US perspective. Ther Clin Risk Manag 2008;4:363-79
   PubMedGoogle Scholar
• Holtzman MJ. Drug development for asthma. Am J Respir Cell Mol Biol 2003;29:163-71
   PubMed Web of Science ®Google Scholar
• Walsh GM. Targeting airway inflammation: novel therapies for the treatment of asthma. Curr Med Chem 2006;13:3105-11
   PubMed Web of Science ®Google Scholar
• Walsh GM. Novel cytokine-directed therapies for asthma. Discov Med 2011;11(59):283-91
   PubMedGoogle Scholar
• O'Byrne PM. The demise of anti IL-5 for asthma, or not. Am J Respir Crit Care Med 2007;176:1059-60
   PubMed Web of Science ®Google Scholar
• Walsh GM. Mepolizumab and eosinophil-mediated disease. Curr Med Chem 2009;16:4774-8
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B, Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-84
   PubMed Web of Science ®Google Scholar
• Nair P, Pizzichini MM, Kjarsgaard M, Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985-93
   PubMed Web of Science ®Google Scholar
• Kim S, Marigowda G, Oren E, Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 2010;125:1336-43
   PubMed Web of Science ®Google Scholar
• Kahn JE, Grandpeix-Guyodo C, Marroun I, Sustained response to mepolizumab in refractory Churg-Strauss syndrome. J Allergy Clin Immunol 2010;125:267-70
   PubMed Web of Science ®Google Scholar
• Castro M, Mathur S, Hargreave F, for the Res-5-0010 Study Group. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011; [Epub ahead of print]
   Google Scholar
• Walsh GM. Reslizumab, a humanized monoclonal anti-IL-5 antibody for the treatment of eosinophil-mediated inflammatory conditions. Curr Opin Mol Ther 2009;11:329-36
   PubMed Web of Science ®Google Scholar
• Kolbeck R, Kozhich A, Koike M, MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 2010;125:1344-53. e2
   PubMed Web of Science ®Google Scholar
• Busse WW, Katial R, Gossage D, Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti–IL-5 receptor antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 2010;125:1237-44
   PubMed Web of Science ®Google Scholar
• Blanchard C, Rothenberg ME. Biology of the eosinophil. Adv Immunol 2009;101:81-121
   PubMed Web of Science ®Google Scholar
• Barrett NA, Austen KF. Innate cells and T helper 2 cell immunity in airway inflammation. Immunity 2009;31(3):425-37
   PubMed Web of Science ®Google Scholar
• Wills-Karp M, Luyimbazi J, Xu X, Interleukin-13: central mediator of allergic asthma. Science 1998;282:2258-60
   PubMed Web of Science ®Google Scholar
• Tliba O, Deshpande D, Chen H, IL-13 enhances agonist evoked calcium signals and contractile responses in airway smooth muscle. Br J Pharmacol 2003;140:1159-62
   PubMed Web of Science ®Google Scholar
• Deshpande DA, Dogan S, Walseth TF, Modulation of calcium signaling by interleukin-13 in human airway smooth muscle: role of CD38/cyclic adenosine diphosphate ribose pathway. Am J Respir Cell Mol Biol 2004;31:36-42
   PubMed Web of Science ®Google Scholar
• Chiba Y, Nakazawa S, Todoroki M, Interleukin-13 Augments Bronchial Smooth Muscle Contractility with an Upregulation of RhoA Protein. Am J Respir Cell Mol Biol 2009;40(2):159-67
   PubMed Web of Science ®Google Scholar
• Kuperman DA, Huang X, Koth LL, Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med 2002;8:885-9
   PubMed Web of Science ®Google Scholar
• Jiang H, Harris MB, Rothman P. IL-4/IL-13 signalling beyond JAK/STAT. J Allergy Clin Immunol 2000;105:1063-70
   PubMed Web of Science ®Google Scholar
• Berry MA, Parker D, Neale N, Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis. J Allergy Clin Immunol 2004;114:1106-9
   PubMed Web of Science ®Google Scholar
• Saha SK, Berry MA, Parker D, Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol 2008;121:685-91
   PubMed Web of Science ®Google Scholar
• Brightling CE, Symon FA, Holgate ST, Interleukin-4 and -13 expression is co-localized to mast cells within the airway smooth muscle in asthma. Clin Exp Allergy 2003;33:1711-16
   PubMed Web of Science ®Google Scholar
• Grunstein MM, Hakonarson H, Leiter J, IL-13-dependent autocrine signaling mediates altered responsiveness of IgE sensitized airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2002;282:L520-8
   PubMed Web of Science ®Google Scholar
• Holgate ST. Has the time come to rethink the pathogenesis of asthma? Curr Opin Allergy Clin Immunol 2010;10(1):48-53
   PubMed Web of Science ®Google Scholar
• Danahay H, Atherton H, Jones G, Interleukin-13 induces a hypersecretory ion transport phenotype in human bronchial epithelial cells. Am J Physiol Lung Cell MolPhysiol 2002;282:L226-36
   PubMed Web of Science ®Google Scholar
• Ahdieh M, Vandenbos T, Youakim A. Lung epithelial barrier function and wound healing are decreased by IL-4 and IL-13 and enhanced by IFN-gamma. Am J Physiol Cell Physiol 2001;281:C2029-38
   PubMed Web of Science ®Google Scholar
• Wenzel SE, Schwartz LB, Langmac EL, Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999;160:1001-8
   PubMed Web of Science ®Google Scholar
• Hashimoto S, Gon Y, Takeshita I, IL-4 and IL-13 induce myofibroblastic phenotype of human lung fibroblasts through c-Jun NH2-terminal kinase-dependent pathway. J Allergy Clin Immunol 2001;107:1001-8
   PubMed Web of Science ®Google Scholar
• Blease K. Therapeutics targeting IL-13 for the treatment of pulmonary inflammation and airway remodeling. Curr Opin Investig Drugs 2008;9:1180-4
   PubMed Web of Science ®Google Scholar
• Corren J, Lemanske RF, Hanania NA, Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Sidhu SS, Yuan S, Innes AL, Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production and collagen gel elasticity in asthma. Proc Natl Acad Sci USA 2010;107:14170-5
   PubMed Web of Science ®Google Scholar
• Takayama G, Arima K, Kanaji T, Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 2006;118:98-104
   PubMed Web of Science ®Google Scholar
• Walsh GM. Emerging drugs for asthma. Expert Opin Emerg Drugs 2008;13:643-53
   PubMed Web of Science ®Google Scholar
• Wenzel SE, Ind PW, Otulana BA, Inhaled pitrakinra, an IL-4/IL-13 antagonist, reduced exacerbations in patients with eosinophilic asthma. Ann Cong Eur Resp Soc 2010;36:abstract #P3980
   Google Scholar
• Corren J, Busse W, Meltzer EO, A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010;181(8):788-96
   PubMed Web of Science ®Google Scholar
• Brightling C, Berry M, Amrani Y. Targeting TNF-alpha: a novel therapeutic approach for asthma. J Allergy Clin Immunol 2008;121:5-10
   PubMed Web of Science ®Google Scholar
• Wenzel SE, Barnes PJ, Bleecker ER, A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009;179(7):549-58
   PubMed Web of Science ®Google Scholar
• Matera MG, Calzetta L, Cazzola M. TNF-alpha inhibitors in asthma and COPD: we must not throw the baby out with the bath water. Pulm Pharmacol Ther 2010;23(2):121-8
   PubMed Web of Science ®Google Scholar
• Holgate ST. A look at the pathogenesis of asthma: the need for a change in direction. Discov Med 2010;9(48):439-47
   PubMedGoogle Scholar